ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN is #1 on TSX today

<< Previous

Bullboard Posts

Next >>

Comment by Annayyaon Mar 26, 2021 4:29pm

205 Views

Post# 32888381

RE:PMN is #1 on TSX today

#1 on TSX again today. PMN is #1 on TSX two days in a row with even higher volume than yesterday. I think we are on to something here as more people are getting to know about this little company. Let's have a three peat and be #1 on Monday next week.

Today's volume is 3.745 million, highest volume of the year again.

User image

Annayya wrote:
Nice to see the share price going up 32% today. PMN is #1 on TSX today. Total volume traded was 3.6 million which is the highest volume day of the year, even higher than the news we got on Monday.